€44m earmarked to combat Africa drug-resistant malaria
The European & Developing
Countries Clinical Trials Partnership (EDCTP) has awarded a new grant to the
new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV).
The consortium will support the
development of new treatments for malaria in the most-at-risk populations,
including babies, patients with severe malaria and those with drug-resistant
infections. The EDCTP grant of €21.9 million is to be matched by funding from
MMV, Novartis and partners.
Over a period of 5 years, the
grant will support the development of a portfolio of projects executed under
the umbrella of the PAMAfrica research consortium. Clinical trial capabilities
in Africa will also be strengthened to ensure each site involved can
effectively operate to ICH-GCP (http://bit.ly/38etrp7) regulatory standards.
The consortium includes seven
research organizations from Burkina Faso, Gabon, Germany, Mozambique, Spain and
Uganda. In addition to Novartis, other pharmaceutical company partners may join
the consortium which will conduct three clinical trials supporting efforts to
build clinical capacity and train scientists across Africa.
The first trial will explore new
combinations of compounds, including new chemical classes, for the treatment of
uncomplicated malaria in adults and children. These compounds are all known to
be fully active against all drug-resistant strains, including the
artemisinin-resistant Kelch13 strains.
The second trial will evaluate a
new generation, rapid-acting treatment for severe malaria, cipargamin, also
known as KAE609, which is being developed by Novartis and supported by a grant
from the Wellcome Trust.
In the third study, a novel
formulation/ratio from Novartis of the current gold standard treatment
artemether-lumefantrine will be tested in newborn infants weighing less than 5kg
or who are malnourished.
Dr Timothy Wells, chief
scientific officer of MMV and the coordinator of the PAMAfrica group, said,
“All three of these research projects address areas of urgent need in malaria
treatment. Antimalarial drug resistance, originally seen in Southeast Asia, is
being reported in Africa and may threaten current treatments. It’s important to
have new therapies that are active against this emerging threat of resistance.
The work on newborn infants and in severe malaria is groundbreaking in bringing
medicines to this neglected group. Thanks to this critical support from EDCTP,
we’re not only able to bring together the necessary African and European
expertise to conduct these projects to address unmet needs, but in doing so, we’re
also able to support the training and development of the next generation of
leaders in clinical malaria research in Africa.”
Dr Michael Makanga, executive director,
EDCTP, said, “Malaria continues needlessly to take 405,000 lives a year and
must remain a global and national priority in endemic countries. We hope our
funding for PAMAfrica will contribute to the development of successful new
treatments that will support malaria eradication while supporting the
development of Africa’s research capacity.”
Caroline Boulton, Global Program
Head, Malaria, Novartis, said, “Despite advances in malaria control, we still
have a long way to go. New antimalarials are urgently needed to tackle rising
parasite resistance to current therapies. In response, Novartis has committed
to advance research and development of a number of next-generation antimalarial
treatments. Partnerships play a critical role in helping to bring these novel
agents forward and we sincerely appreciate the crucial support of EDCTP to this
process.”
Recent reports from the World
Health Organization (WHO) and the Lancet Commission on Malaria Eradication have
made it clear that defeating malaria will demand new tools, including new and
better medicines.
The 2019 WHO World Malaria Report
states that global malaria deaths are declining at a slower rate than in recent
years and highlights the need for improved interventions to treat the most
vulnerable populations, including babies.
The PAMAfrica consortium was
created to take up this challenge and implements a flexible portfolio approach
to the development of new malarials. It brings together expertise from its
various African and European partners. The consortium activities will be
publicised under a dedicated logo.
The following organisations are
partners in the PAMAfrica consortium: Centre de Recherches Médicales de
Lambaréné (CERMEL), Gabon; Centre National de la Recherche Scientifique et
Technologique (CNRST), Burkina Faso; Eberhard Karls Universität Tübingen
(EKUT), Germany; Manhiça Health Research Centre, Mozambique; Fundación Privada
Instituto de Salud Global de Barcelona (ISGlobal), Spain; Groupe de Recherche
Action en Santé (GRAS), Ouagadougou, Burkina Faso; Infectious Diseases Research
Collaboration (IDRC), Tororo, Uganda; Medicines for Malaria Venture, Geneva,
Switzerland; and Novartis, Basel, Switzerland.
Comments
Post a Comment